John S. Coon

7.6k total citations · 1 hit paper
150 papers, 6.0k citations indexed

About

John S. Coon is a scholar working on Molecular Biology, Oncology and Surgery. According to data from OpenAlex, John S. Coon has authored 150 papers receiving a total of 6.0k indexed citations (citations by other indexed papers that have themselves been cited), including 55 papers in Molecular Biology, 52 papers in Oncology and 27 papers in Surgery. Recurrent topics in John S. Coon's work include Endometriosis Research and Treatment (22 papers), Uterine Myomas and Treatments (19 papers) and Lung Cancer Treatments and Mutations (17 papers). John S. Coon is often cited by papers focused on Endometriosis Research and Treatment (22 papers), Uterine Myomas and Treatments (19 papers) and Lung Cancer Treatments and Mutations (17 papers). John S. Coon collaborates with scholars based in United States, Japan and Philippines. John S. Coon's co-authors include Ronald S. Weinstein, Pavel G. Komarov, Roman V. Kondratov, Andrei V. Gudkov, Mikhail V. Chernov, Elena A. Komarova, Serdar E. Bulun, Ping Yin, Lela Buckingham and Jack L. Summers and has published in prestigious journals such as Science, Proceedings of the National Academy of Sciences and Journal of Clinical Investigation.

In The Last Decade

John S. Coon

148 papers receiving 5.9k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

A Chemical Inhibitor of p53 That Protects Mice from the Side Effects of Cancer Therapy

1999 1.1k citations Pavel G. Komarov, John S. Coon et al. profile →

Peers

Countries citing papers authored by John S. Coon

Since Specialization

Citations

This map shows the geographic impact of John S. Coon's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by John S. Coon with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites John S. Coon more than expected).

Fields of papers citing papers by John S. Coon

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by John S. Coon. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by John S. Coon. The network helps show where John S. Coon may publish in the future.

Co-authorship network of co-authors of John S. Coon

This figure shows the co-authorship network connecting the top 25 collaborators of John S. Coon. A scholar is included among the top collaborators of John S. Coon based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with John S. Coon. John S. Coon is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Estrogen receptor-α ablation reverses muscle fibrosis and inguinal hernias 2025 ·Journal of Clinical Investigation ·Tanvi Potluri, (unknown), Ping Yin, John S. Coon, Jonah J. Stulberg, Yang Dai, David Escobar, Richard L. Lieber, Hong Zhao, Serdar E. Bulun	1
2	Therapeutic targeting of the tryptophan-kynurenine-aryl hydrocarbon receptor pathway with apigenin in MED12-mutant leiomyoma cells 2025 ·Cancer Gene Therapy ·Takashi Iizuka, (unknown), (unknown), John S. Coon, (unknown), (unknown), Mazhar Adli, Serdar E. Bulun, (unknown)	1
3	MED12 mutation activates the tryptophan/kynurenine/AHR pathway to promote growth of uterine leiomyomas 2023 ·JCI Insight ·(unknown), (unknown), (unknown), (unknown), John S. Coon, Shimeng Liu, Takashi Iizuka, Olívia Wu, (unknown), (unknown), Debabrata Chakravarti, Thomas G. Boyer, Yang Dai, Serdar E. Bulun, Ping Yin	6
4	Tryptophan 2,3-Dioxygenase-2 in Uterine Leiomyoma: Dysregulation by MED12 Mutation Status 2022 ·Reproductive Sciences ·Anne P. Hutchinson, Ping Yin, (unknown), John S. Coon, (unknown), Shimeng Liu, Serdar E. Bulun	13
5	Targeting DNA Methylation Depletes Uterine Leiomyoma Stem Cell–enriched Population by Stimulating Their Differentiation 2020 ·Endocrinology ·Shimeng Liu, Ping Yin, (unknown), (unknown), (unknown), John S. Coon, Hong Zhao, Ali Shilatifard, Yang Dai, Serdar E. Bulun	18
6	Ovarian steroids, stem cells and uterine leiomyoma: therapeutic implications 2014 ·Human Reproduction Update ·Molly B. Moravek, Ping Yin, Masanori Ono, John S. Coon, Matthew T. Dyson, Antònia Navarro, Erica E. Marsh, Debabrata Chakravarti, Julie Kim, Jian Wei, Serdar E. Bulun	115
7	Fenretinide: A Novel Treatment for Endometrial Cancer 2014 ·PLoS ONE ·Navdha Mittal, Saurabh Malpani, Matthew T. Dyson, Masanori Ono, John S. Coon, Julie Kim, Julian C. Schink, Serdar E. Bulun, Mary Ellen Pavone	16
8	Impaired Fetoplacental Angiogenesis in Growth-Restricted Fetuses With Abnormal Umbilical Artery Doppler Velocimetry Is Mediated by Aryl Hydrocarbon Receptor Nuclear Translocator (ARNT) 2014 ·The Journal of Clinical Endocrinology & Metabolism ·Emily Su, Hong Xin, Ping Yin, Matthew T. Dyson, John S. Coon, Kathryn N. Farrow, Karen K. Mestan, Linda M. Ernst	33
9	Transcription Factor KLF11 Integrates Progesterone Receptor Signaling and Proliferation in Uterine Leiomyoma Cells 2010 ·Cancer Research ·Ping Yin, Zhihong Lin, Scott Reierstad, Wu Ju, Hiroshi Ishikawa, Erica E. Marsh, Joy Innes, You-Hong Cheng, (unknown), John S. Coon, Julie Kim, Debabrata Chakravarti, Serdar E. Bulun	71
10	Enhancement of a multianalyte serum biomarker panel to identify lymph node metastases in non‐small cell lung cancer with circulating autoantibody biomarkers 2010 ·International Journal of Cancer ·(unknown), (unknown), Anthony W. Kim, Bao‐Shiang Lee, Sanjib Basu, John S. Coon, (unknown), (unknown), (unknown), Cristina Fhied, Christopher Chang, (unknown), L. Penfield Faber, Philip Bonomi, (unknown), Jeffrey A. Borgia	28
11	Topoisomerase II alpha gene copy loss has adverse prognostic significance in ERBB2-amplified breast cancer: a retrospective study of paraffin-embedded tumor specimens and medical charts 2008 ·Journal of Hematology & Oncology ·Lydia Usha, (unknown), Larry E. Morrison, Ruta Rao, Kris Jacobson, (unknown), Sanjib Basu, John S. Coon	5
12	X‐ray structure of the T. Aquaticus Ftsy:GDP complex suggests functional roles for the C‐terminal helix of the SRP GTPases 2006 ·Proteins Structure Function and Bioinformatics ·(unknown), John S. Coon, Pamela J. Focia, Douglas Freymann	25
13	Amplification and overexpression of topoisomerase IIalpha predict response to anthracycline-based therapy in locally advanced breast cancer. 2002 ·PubMed ·John S. Coon, Elizabeth A. Marcus, Shalina Gupta-Burt, Steven Seelig, Kris Jacobson, Shande Chen, (unknown), (unknown), Harvey D. Preisler	145
14	Prognostic Significance of p27 Expression in Carcinoma of the Oral Cavity and Oropharynx 1999 ·The Laryngoscope ·Thiagarajan Venkatesan, (unknown), David D. Caldarelli, William R. Panje, James C. Hutchinson, Shande Chen, John S. Coon	41
15	Activation of the LRP (lung resistance-related protein) gene by short-term exposure of human leukemia cells to phorbol ester and cytarabine. 1998 ·PubMed ·Pavel G. Komarov, Аlexander А. Shtil, Oksana Holian, (unknown), Lela Buckingham, Eugene Mechetner, Igor B. Roninson, John S. Coon	20
16	Reversal of Multidrug-Resistance Phenotype by Surfactants: Relationship to Membrane Lipid Fluidity 1995 ·Archives of Biochemistry and Biophysics ·Pradeep K. Dudeja, K.M. Anderson, Jack Harris, Lela Buckingham, John S. Coon	128
17	Variable effects of sodium butyrate on the expression and function of the MDR 1 (P‐glycoprotein) gene in colon carcinoma cell lines 1993 ·International Journal of Cancer ·Thomas O. Frommel, John S. Coon, T Tsuruo, Igor B. Roninson	31
18	Multidrug resistance activity in human lymphocytes 1991 ·Human Immunology ·John S. Coon, (unknown), Steven D. Bines, Penelope N. Markham, Anita S. Chong, Howard M. Gebel	89
19	P-glycoproteins in pathology: The multidrug resistance gene family in humans 1990 ·Human Pathology ·Ronald S. Weinstein, Jerome R. Kuszak, Larry Kluskens, John S. Coon	138
20	Interinstitutional variability in DNA flow cytometric analysis of tumors. The National Cancer Institute's flow cytometry network experience 1988 ·Cancer ·John S. Coon, Arline D. Deitch, (unknown), Leopold G. Koss, Myron R. Melamed, Jay E. Reeder, Ronald S. Weinstein, Leon L. Wheeless, Robert P. Wersto	42

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact